Thu.Sep 19, 2024

article thumbnail

Top three trends in precision medicine

Pharmaceutical Technology

An innovative approach to healthcare, precision medicine is a new medical model that takes into account individual differences in genes, environments, and lifestyles to drive better outcomes through medicine.

Medicine 264
article thumbnail

Can the Fed’s rate cut change biotech’s ‘new normal’?

Bio Pharma Dive

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

321
321
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DCA Telangana raids & seizes illegally made cough syrups in Hyderabad

AuroBlog - Aurous Healthcare Clinical Trials blog

Home Editorial Services Interview Q&A Chronicle Specials Pharma Mart ePharmail Archives Join Pharma | Login Home > TopNews you can get e-magazine links on WhatsApp.

article thumbnail

Roche’s Xofluza reduces flu transmission in Phase 3 study

Bio Pharma Dive

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in a global Phase 3 trial.

Trials 263
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nod

Pharmaceutical Technology

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with polyangiitis.

article thumbnail

23andMe’s independent board directors resign

Bio Pharma Dive

In a letter to CEO Anne Wojcicki, the directors said they’d resign “rather than have a protracted and distracting difference of view with you” about the company’s future.

246
246

More Trending

article thumbnail

Startup from George Church’s lab raises $75M to develop ‘supercell’ medicines

Bio Pharma Dive

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster than by current methods with a simpler process.

Medicine 189
article thumbnail

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Pharmaceutical Technology

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

article thumbnail

4D Molecular data ‘bode well’ for eye gene therapy, but shares fall

Bio Pharma Dive

Shares dropped by as much as one-quarter Thursday after the biotech shared longer-term results for a gene therapy it’s developing for wet AMD.

article thumbnail

Cancer therapies for young adults: The need for tailored treatment and diversity

Pharmaceutical Technology

Statistics show incidences of cancer are rising in younger demographics.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

New migraine drugs less effective than previous generation of triptan meds: BMJ study

Fierce Pharma

A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migra | A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.

Drugs 129
article thumbnail

FDA approves Accord BioPharma’s HERCESSI for cancer treatment

Pharmaceutical Technology

Accord BioPharma received FDA approval for 420mg HERCESSI, a biosimilar to Herceptin to treat various kinds of HER2-overexpressing cancers.

article thumbnail

Granules India scolded over truckloads of torn manufacturing documents after recent FDA inspection

Fierce Pharma

From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it. | Earlier this month, Granules was slapped with a Form 483 following an inspection of its Telangana facility in India that ran from Aug. 26 to Sept. 6. The FDA’s report cites six observations around poor quality control procedures, subpar cleaning, cross-contamination risks and more.

article thumbnail

Lupin and Takeda to commercialise Vonoprazan in India

Pharmaceutical Technology

Lupin has announced a non-exclusive patent licence agreement with Takeda for the commercialisation of Vonoprazan Tablets in India.

130
130
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Neuralink gets breakthrough tag for sight-restoring implant

pharmaphorum

Neuralink gets FDA breakthrough status for an implantable chip called Blindsight that promises to restore eyesight to the blind

111
111
article thumbnail

FDA approves MSD’s KEYTRUDA as first-line MPM treatment

Pharmaceutical Technology

The US FDA has granted approval for MSD’s KEYTRUDA regimen as a first-line treatment for malignant pleural mesothelioma (MPM).

article thumbnail

Vanda slams FDA rejection of gastroparesis drug

pharmaphorum

FDA turns down Vanda Pharma's tradipitant for gastroparesis, prompting a furious response from the company

Drugs 111
article thumbnail

Gavi to obtain 500,000 mpox vaccine doses from Bavarian Nordic

Pharmaceutical Technology

Gavi has entered into an agreement with Bavarian Nordic to secure 500,000 doses of the MVA-BN mpox vaccine.

Vaccine 130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

ICER mulls GSK COPD drugs ahead of next Medicare negotiation

pharmaphorum

ICER will preempt the next Medicare drug pricing round with a 'special report' on two COPD drugs from GSK

Drugs 111
article thumbnail

Gilead's Kite exits China cell therapy joint venture with Fosun Pharma

Fierce Pharma

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma. | Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the cell therapy-focused joint venture with Fosun Pharma.

105
105
article thumbnail

Respiratory biotech Upstream joins Nasdaq IPO surge

pharmaphorum

Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, seeking funds for its rival to respiratory drug Tezspire.

Drugs 105
article thumbnail

How to Develop a Competitive Generic Drug Portfolio

Drug Patent Watch

The generic drug market in the United States is characterized by significant price volatility and shortages, driven by the structure of the market and the incentives for manufacturers. To address these issues, several market-based proposals have been put forth to optimize generic drug cost and availability.

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

Oncologica to advance urine-based prostate cancer screening test

Pharma Times

There is currently no national screening programme for the disease in the UK

101
101
article thumbnail

Supply chain resilience in pharma: Delivering consistency amidst global events

pharmaphorum

Explore how the pharmaceutical industry is ensuring supply chain resilience to maintain consistency despite global events. Learn more about strategies and practices implemented to address challenges and ensure reliable delivery of pharmaceutical products.

article thumbnail

World Cancer Research Day 2024: New Cancer Drugs and Clinical Milestones

XTalks

World Cancer Research Day 2024, observed on September 24, highlights innovation under the theme “Innovation In Cancer Research Drives Progress Toward Health Equity.” This year’s theme focuses on the need for breakthroughs across all stages of cancer care, from prevention to treatment. As new research reaches more patients, thanks to policies and technological advancements, it’s improving survival rates and bringing us closer to health equity around the world. 2024 has seen significant US F

article thumbnail

Insilico Medicine claims phase 2 win for AI-designed drug

Outsourcing Pharma

The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met its primary endpoint.

article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Pricing and logistics: The challenges of getting mpox vaccines to the front line

BioPharma Reporter

Although vaccines already exist to prevent mpox, high prices and the risk of side effects make it difficult to roll them out in the regions that need them most. Vaccine developers are working to offer better options.

Vaccine 85
article thumbnail

Daiichi Sankyo's Vanflyta gets NICE nod for leukaemia

pharmaphorum

Daiichi Sankyo's FLT3 inhibitor Vanflyta has been recommended for NHS use as a treatment for a specific form of acute myeloid leukaemia (AML) in England and Wales, the first countries in Europe to authorise use of the drug after a health technology assessment (HTA) review.

Drugs 83
article thumbnail

NuraBio closes $140m fundraising to develop neuroprotective drugs

Outsourcing Pharma

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, shortly after successfully completing a first phase 1 clinical trial.

article thumbnail

Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence

BioPharma Reporter

Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive, HER2-negative) stage two or three early breast cancer, who are at high risk of cancer recurrence.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.